The osteoporosis drugs most commonly linked to jawbone death are bisphosphonates — medications like Fosamax, Boniva, and Actonel that millions of older adults take to prevent fractures. These drugs, along with the newer injectable Prolia (denosumab), can cause a condition called osteonecrosis of the jaw, where bone tissue literally dies because blood supply is cut off. The risk is low for most osteoporosis patients, but it climbs sharply for people on high-dose intravenous versions used in cancer treatment, and it spikes dramatically after dental procedures like tooth extractions. For families navigating dementia care, this matters more than you might think.
Cognitive decline often means dental hygiene suffers, routine dental visits get skipped, and medication management becomes complicated. A person with dementia may not be able to report early symptoms of jaw pain or loose teeth — the very warning signs that could catch osteonecrosis before it becomes severe. If your loved one is on one of these bone drugs, understanding the risks and knowing what to do before dental work could prevent a painful and difficult-to-treat complication. This article covers which specific drugs carry the highest risk, who is most vulnerable, what recent research from 2025 tells us about drug holidays and prevention, and the practical steps caregivers should take to protect someone who cannot fully advocate for themselves.
Table of Contents
- Which Osteoporosis Drugs Cause Jawbone Death, and How Common Is It?
- Why Dental Procedures Are the Biggest Trigger — and When the Risk Doesn’t Apply
- The Dementia Connection — Why Cognitive Decline Makes This Risk Harder to Manage
- Drug Holidays Before Dental Surgery — What 2025 Research Says About Timing
- Warning Signs, Diagnosis, and Why Late Detection Is Common in Dementia Patients
- The Legal History of Fosamax and What It Means for Patients Today
- Looking Ahead — Better Protocols and Remaining Gaps
- Conclusion
- Frequently Asked Questions
Which Osteoporosis Drugs Cause Jawbone Death, and How Common Is It?
Bisphosphonates are the primary class of drugs implicated in osteonecrosis of the jaw. The most widely prescribed oral versions include Fosamax (alendronate), Boniva (ibandronate), and Actonel (risedronate). Intravenous bisphosphonates — Zometa (zoledronic acid) and Reclast (pamidronate) — carry a much higher risk and are often used in cancer patients to prevent bone complications from metastatic disease. These drugs work by slowing the breakdown of bone, which sounds beneficial until you realize the jaw relies on constant bone remodeling to stay healthy, particularly around the teeth. When that remodeling process is suppressed too aggressively, the bone can lose its blood supply and begin to die. For osteoporosis patients on standard oral bisphosphonates, the incidence of osteonecrosis of the jaw is quite rare — estimated at less than one case per 100,000 person-years of exposure, which may not even exceed the natural background rate. That is reassuringly low.
But compare that to cancer patients receiving high-dose IV bisphosphonates, where the incidence jumps to between 1 and 12 percent depending on dose and duration. According to data compiled by StatPearls and the University of Alabama at Birmingham, 94 percent of all bisphosphonate-related jawbone osteonecrosis cases have occurred in cancer patients treated with IV zoledronic acid or pamidronate — not in the typical osteoporosis patient taking a weekly pill. Denosumab, sold as Prolia for osteoporosis and Xgeva for cancer-related bone loss, is a newer drug that works differently from bisphosphonates but carries its own jaw risks. A Swiss registry study found that patients taking denosumab had 3.49 times the risk of developing osteonecrosis of the jaw compared to bisphosphonate users. Among cancer patients specifically, National Cancer Institute data showed that people on denosumab were nearly five times as likely to develop the condition. This is worth knowing because denosumab is increasingly prescribed as an alternative to bisphosphonates, and patients may assume the newer drug is safer across the board. In this particular respect, it is not.
Why Dental Procedures Are the Biggest Trigger — and When the Risk Doesn’t Apply
The single most important risk factor for developing osteonecrosis of the jaw while on these medications is dental surgery. Tooth extraction precedes jawbone osteonecrosis in over 50 percent of cases and is associated with a 33-fold increase in risk. that statistic, drawn from a 2024 study published in PubMed, is striking — a routine dental procedure that most people undergo without a second thought becomes genuinely dangerous when bisphosphonates or denosumab have been suppressing bone turnover for years. The posterior mandible, or the back of the lower jaw, is the most vulnerable site, likely because that area has less blood supply and is subject to greater mechanical stress from chewing. However, if your loved one is only taking an oral bisphosphonate for osteoporosis and has been on it for less than two years, the risk of developing jawbone osteonecrosis after a dental procedure remains very low. The danger escalates meaningfully after 24 months of continuous treatment.
One study identified the highest synergistic risk in patients who had been on these drugs for 24 months or longer, had less than three months of drug interruption before the procedure, and had a posterior mandibular tooth extracted. That specific combination of factors represents the worst-case scenario, not every patient who takes Fosamax and needs a filling. this distinction matters for caregivers trying to weigh risks. A person with early-stage dementia who has been on alendronate for six months and needs a cavity filled is in a very different risk category than someone who has been on IV zoledronic acid for three years and needs a molar pulled. Dental cleanings, simple restorations, and non-invasive procedures generally do not carry the same level of concern. The danger is concentrated around procedures that expose or disturb the jawbone — extractions, implant placement, and periodontal surgery that involves bone.
The Dementia Connection — Why Cognitive Decline Makes This Risk Harder to Manage
Dementia complicates osteoporosis drug safety in ways that are easy to overlook. Consider this scenario: a woman in her late seventies with moderate Alzheimer’s has been on Fosamax for four years. Her daughter manages her medications but hasn’t thought to mention the bisphosphonate to the dentist. The woman develops a tooth infection and needs an extraction. She can’t clearly communicate the jaw pain she’s been feeling for weeks, and the dental team doesn’t know to take extra precautions. After the extraction, the socket doesn’t heal. Exposed bone appears. What follows is months of treatment for a condition that might have been prevented with a simple medication review and a drug holiday.
This is not a hypothetical edge case. Older adults with dementia are at elevated risk for several of the known cofactors that increase osteonecrosis likelihood: poor dental hygiene (because they forget or resist brushing), periodontal disease (because dental visits become less frequent as cognition declines), denture use (which creates pressure on the jawbone), and concurrent corticosteroid use (common in older adults with multiple health conditions). Diabetes and smoking, two other recognized risk factors according to the American Dental Association, are also prevalent in this population. The cognitive impairment itself doesn’t directly cause osteonecrosis, but it creates conditions where the risk compounds silently. Caregivers managing medications for someone with dementia should specifically flag bisphosphonates and denosumab on any medical or dental intake form. Do not assume the dental office will cross-reference the medication list. In a 2025 real-world retrospective cohort study using the TriNetX global network, researchers confirmed that medication-related osteonecrosis of the jaw remains an ongoing concern with both bisphosphonates and denosumab in osteoporosis therapy. The condition has not been solved — it is simply under-discussed.
Drug Holidays Before Dental Surgery — What 2025 Research Says About Timing
One of the most actionable findings from recent research involves drug holidays — intentionally pausing bisphosphonate or denosumab treatment before invasive dental work. A 2025 study published in Nature Communications found that pausing IV bisphosphonate treatment for more than 90 days substantially lowered the risk of osteonecrosis, with the lowest risk observed when the pause exceeded one year. Current guidelines from the American Association of Oral and Maxillofacial Surgeons recommend a minimum three-month drug holiday before extractions, implant placement, or periodontal surgery that involves bone manipulation. The tradeoff is real, though, and caregivers need to understand it clearly. Stopping a bisphosphonate or denosumab means the skeleton loses some of its protection against fractures. For a person with dementia who is already at high fall risk, a hip fracture can be catastrophic — it frequently accelerates cognitive decline and leads to loss of independence or death.
So the decision to pause bone medication before dental surgery is not straightforward. It requires a conversation between the prescribing physician (usually an endocrinologist, rheumatologist, or primary care doctor) and the dentist or oral surgeon, ideally with the caregiver facilitating that communication. For oral bisphosphonates taken for less than two years, the AAOMS guidelines generally do not recommend a drug holiday before dental procedures because the accumulated risk is still low. For patients who have been on these medications for more than two years, or who have additional risk factors like corticosteroid use, the calculus shifts. Denosumab presents an additional complication: unlike bisphosphonates, which linger in bone for years after discontinuation, denosumab’s effects wear off within about six months, and stopping it can trigger a rebound increase in bone loss and even vertebral fractures. Any drug holiday involving Prolia needs to be carefully managed and should not be done without medical supervision.
Warning Signs, Diagnosis, and Why Late Detection Is Common in Dementia Patients
Osteonecrosis of the jaw typically presents with exposed bone in the mouth that persists for more than eight weeks, often accompanied by pain, swelling, infection, numbness, or loosening of teeth. In its early stages, a patient might notice a dull ache in the jaw, difficulty chewing, or a strange taste in the mouth from draining infection. The problem is that a person with moderate to advanced dementia may not be able to articulate any of these symptoms. They might simply refuse food, become agitated during meals, or pull at their face — behaviors that can easily be misattributed to the dementia itself rather than recognized as signs of an oral health emergency. Caregivers should make a habit of visually inspecting the mouth of anyone with dementia who is on bisphosphonates or denosumab, particularly after any dental work. Look for areas of whitish or yellowish exposed bone along the gum line, especially in the lower jaw.
Persistent bad breath, swelling along the jawline, or new difficulty with denture fit can also be warning signs. If you suspect something, request a referral to an oral and maxillofacial surgeon rather than waiting for a general dentist to evaluate it — osteonecrosis management often requires specialized care including debridement, antibiotics, and sometimes surgical removal of dead bone. A limitation worth noting: there is no reliable screening test or imaging study that can predict who will develop osteonecrosis before it happens. Cone beam CT scans can identify early bone changes, but they are not routinely performed on asymptomatic patients. The condition is diagnosed clinically, which means it is typically caught only after symptoms have already appeared. For dementia patients who cannot report symptoms, this makes proactive prevention — dental exams before starting medication, good oral hygiene, and careful planning around dental procedures — even more critical.
The Legal History of Fosamax and What It Means for Patients Today
Merck, the manufacturer of Fosamax, settled approximately 1,200 osteonecrosis of the jaw lawsuits for $27.7 million around 2013. The federal multidistrict litigation (MDL No. 1789) formally closed in 2018. As of 2025 and into 2026, most law firms are no longer accepting new bisphosphonate-related jaw injury cases, which signals that the major wave of litigation has concluded.
This does not mean the condition has gone away — it means the legal system has largely processed the claims that were going to be filed. For caregivers, the practical takeaway is this: if your loved one develops osteonecrosis of the jaw from a bisphosphonate or denosumab, the path to legal compensation is now much narrower than it was a decade ago. The more important focus is prevention. Ensure that prescribing doctors and dental providers are communicating, that medication lists are current and shared, and that drug holidays are discussed before any invasive dental procedure.
Looking Ahead — Better Protocols and Remaining Gaps
Research into medication-related osteonecrosis of the jaw is still evolving. The 2025 studies on drug holiday timing and real-world incidence data represent meaningful progress, but significant gaps remain. There is still no consensus on the optimal length of a drug holiday, no reliable biomarker to identify patients at highest risk before they develop symptoms, and limited data on how dementia-specific factors like reduced oral care and delayed symptom reporting affect outcomes.
As the population ages and the overlap between dementia, osteoporosis, and complex medication regimens grows, this is an area that deserves more clinical attention than it currently receives. What is encouraging is that professional organizations like the AAOMS and ADA have issued increasingly specific guidance on prevention, and the conversation around drug holidays has shifted from controversial to standard practice in high-risk patients. For families managing dementia alongside other chronic conditions, staying informed about these evolving recommendations — and making sure every provider on the care team knows about every medication — remains the best defense against a preventable complication.
Conclusion
Bisphosphonates and denosumab are effective at preventing the fractures that can devastate older adults, but they carry a real if uncommon risk of osteonecrosis of the jaw — a condition where jawbone dies from lack of blood supply. The risk is lowest for osteoporosis patients on oral medications for less than two years and highest for cancer patients on intravenous formulations, but it rises for everyone with treatment duration, dental procedures, and compounding factors like poor oral hygiene, corticosteroid use, and diabetes.
For people with dementia, the danger is amplified by their inability to maintain dental care independently or report early warning signs. The most important steps a caregiver can take are straightforward: ensure a comprehensive dental exam happens before these medications are started, keep every provider informed about the full medication list, discuss drug holidays before any invasive dental work in patients who have been on treatment for more than two years, and visually check the mouth regularly for signs of exposed bone or infection. These medications remain valuable tools for fracture prevention, but they require active, informed management — especially when the person taking them cannot manage that vigilance on their own.
Frequently Asked Questions
Can I get osteonecrosis of the jaw from taking Fosamax for osteoporosis?
It is possible but very rare. The estimated incidence for osteoporosis patients on oral bisphosphonates is less than one case per 100,000 person-years of exposure. The risk increases with treatment duration beyond 24 months and with invasive dental procedures.
Is Prolia (denosumab) safer than bisphosphonates for jaw health?
No. In fact, a Swiss registry study found denosumab carried 3.49 times the risk of osteonecrosis of the jaw compared to bisphosphonates. Among cancer patients, NCI data showed denosumab users were nearly five times as likely to develop the condition. Prolia has advantages in other areas, but jaw safety is not one of them.
Should my parent stop their bone medication before getting a tooth pulled?
If they have been on a bisphosphonate or denosumab for more than two years, current AAOMS guidelines recommend discussing a three-month drug holiday before extractions or other invasive dental procedures. This decision should involve both the prescribing physician and the dental provider, as stopping medication also increases fracture risk.
How do I check for osteonecrosis of the jaw in someone with dementia?
Gently inspect the mouth for areas of exposed whitish or yellowish bone along the gum line, especially in the lower jaw. Watch for signs like food refusal, agitation during meals, persistent bad breath, jaw swelling, or changes in denture fit. If you see anything concerning, request a referral to an oral and maxillofacial surgeon.
Does a drug holiday eliminate the risk of osteonecrosis?
It reduces the risk but does not eliminate it entirely. A 2025 study in Nature Communications found that pausing IV bisphosphonates for more than 90 days substantially lowered the risk, with the greatest benefit seen when the pause exceeded one year. However, bisphosphonates remain in bone tissue for years after discontinuation, so some residual risk persists.
Are dental cleanings and fillings safe while on these medications?
Generally, yes. The elevated risk is associated with procedures that disturb or expose the jawbone — primarily extractions, dental implant placement, and periodontal surgery involving bone. Routine cleanings, fillings, and non-invasive procedures are not considered high-risk triggers for osteonecrosis.
